ArrowHead Pharma (ARWR.US) Latest Stock News - Major News Analysis

Quote List Quote List

Event Tracking

Dec9

Arrowhead Pharmaceuticals Inc. Director Michael S. Perry Sells Common Stock

23:05

Analyst Patrick Trucchio Reiterates Buy Rating on Arrowhead Pharmaceuticals with a Target Price of $85

17:03

Dec8

Morgan Stanley Maintains Hold Rating on Arrowhead Pharmaceuticals with Price Target of $48

21:52

Arrowhead Pharmaceuticals Launches ARO-MAPT Clinical Trial for Alzheimer's Disease

12:30

Arrowhead Pharmaceuticals Announces First Commercial Launch of RNA Interference Therapy REDEMPLO® in 2025

02:05

Dec3

HC Wainwright Raises Arrowhead Pharmaceuticals' Target Price to $85

19:56

Schedules & Filings

Schedules

Filings

Nov25

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 256.47 M, Net Income -23.75 M, EPS -0.1741

Aug7

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 27.77 M, Net Income -175.24 M, EPS -1.2603

May12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 542.71 M, Net Income 370.45 M, EPS 2.75

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change